Table 1 Patient characteristics

Age (years)

Median (range)

40 (25–55)

Race

White

5

Black

4

Hispanic

3

Asian

1

Clinical T stage

T1

2

T2

9

T3

2

Clinical N stage

N0

12

N1

1

N2

0

N3

0

Clinical stage

I

2

II

9

III

2

Estrogen receptor

Positive

5

Negative

8

Progesterone receptor

Positive

3

Negative

10

BRCA (1 or 2)

1

10

2

3

Histology

Ductal

12

Metaplastic

1

Grade

1

0

2

1

3

12

Compliance

100%

12

57%

1

Days from last talazoparib to first day of chemotherapy

Median (range)

8 (1–23)*

Chemotherapy regimen used

AC followed or preceded by weekly taxol

13

Addition of carboplatin to weekly taxol

6

Dose reduction of talazoparib

One patient

25% Dose reduction secondary to cytopenia that occurred 48 days from the initiation of therapy after holding therapy for 7 days and decreased to grade I